Evaluation of Premarket-Identified Serious Risks for Drugs and Biologics Using FDA Surveillance Systems
Year: 2026
Type: article
Study design: Observational Study
Abstract: This cross-sectional study examines the use and sufficiency of US Food and Drug Administration (FDA) postmarket surveillance systems for further assessing serious risks found at product approval between 2016 and 2025.
Source: JAMA Internal Medicine
Institutions: Emory University, Yale University, Yale New Haven Hospital
Language: English
Subfield: Toxicology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7234452154
